Category Archive

Introduction In the pharmaceutical world, Phase 2 marks a critical turning point. It’s the stage where proof-of-concept data emerges, commercial potential becomes clearer, and teams must decide whether to advance into the high-cost, high-stakes environment of Phase 3. But moving forward without a deep understanding of the competitive landscape is a gamble. This is where competitive intelligence (CI) comes into …

What is Trend Analysis? Organizations often notice change, but struggle to interpret it. Competitors launch new products, consumer behaviors shift, and technologies emerge faster than adoption cycles. Without structure, these signals feel like noise. Trend analysis provides the discipline to evaluate them systematically and turn change into clarity. At its core, trend analysis is the process of monitoring external signals …

Introduction Business leaders face no shortage of information. Data pours in from markets, competitors, customers, and internal systems. Every department has an opinion. Timelines are tight, politics add noise, and projects demand clarity that is often missing. The challenge is not a lack of insight but a lack of prioritization. Too often, organizations stall at the very moment action is …

Software companies operate in a fast-moving environment. Competitors release new features in quick cycles, customers expect seamless integrations, and pricing models shift as buyers evaluate options side-by-side. With so much happening at once, the challenge is deciding what should be prioritized. The Threat & Opportunity Prioritization Matrix provides a way to bring structure to this process. It evaluates potential scenarios …

Budgeting, Planning, and Benchmarking During annual budgeting and planning, executives gather in conference rooms to defend last year’s baseline, avoid Finance’s cuts, and argue over priorities. Too often, the result reflects politics not performance. Integrating benchmarking into this process offers a way out of that cycle. In the budgeting context, benchmarking means anchoring decisions in relevant external reference points including …

In the pharmaceutical industry, the stakes for a new product launch could not be higher. Years of research, hundreds of millions in investment, and the hopes of both patients and shareholders ride on a successful entry into the market. Yet the statistics are sobering: industry studies show that 56% of drug launches fail to meet their pre-launch expectations. In competitive …

Pharmaceutical launches represent years of research, development, and investment — but the commercial reality can be unforgiving. Even with groundbreaking science, many products struggle to achieve their market potential because of missteps that occur in the final stages before and after launch. Drawing on Sedulo Group’s experience supporting dozens of life sciences clients through successful launches, we’ve identified five pitfalls …

For most pharmaceutical products, the window for establishing a successful launch trajectory is shockingly short, roughly six months after regulatory approval. By that point, your uptake curve has formed, key prescribers have made their decisions, and payer access dynamics are largely locked in. Industry research shows that 80% of underperforming launches never recover after the first six months. This is …